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Abstract
Background: The aim of this study was to determine glutathione levels and antioxidant enzyme activities in the
drug-naive first-episode patients with schizophrenia in comparison with healthy control subjects.
Methods: It was a case-controlled study carried on twenty-three patients (20 men and 3 women, mean age = 29.3
± 7.5 years) recruited in their first-episode of schizophrenia and 40 healthy control subjects (36 men and 9 women,
mean age = 29.6 ± 6.2 years). In patients, the blood samples were obtained prior to the initiation of neuroleptic
treatments. Glutathione levels: total glutathione (GSHt), reduced glutathione (GSHr) and oxidized glutathione
(GSSG) and antioxidant enzyme activities: superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT)
were determined by spectrophotometry.
Results: GSHt and reduced GSHr were significantly lower in patients than in controls, whereas GSSG was
significantly higher in patients. GPx activity was significantly higher in patients compared to control subjects. CAT
activity was significantly lower in patients, whereas the SOD activity was comparable to that of controls.
Conclusion: This is a report of decreased plasma levels of GSHt and GSHr, and impaired antioxidant enzyme
activities in drug-naive first-episode patients with schizophrenia. The GSH deficit seems to be implicated in
psychosis, and may be an important indirect biomarker of oxidative stress in schizophrenia early in the course of
illness. Finally, our results provide support for further studies of the possible role of antioxidants as neuroprotective
therapeutic strategies for schizophrenia from early stages.
Background
There is strong evidence that oxygen free radicals may
play an important role in the pathophysiology of major
mental illnesses such as schizophrenia [1,2]. Oxyradicals
have a very short life span and usually are inactivated or
scavenged by antioxidants before they can inflict damage
to lipids, proteins or nucleic acids. The human body has
a complex antioxidant defense system (AODS) that
includes the antioxidant enzymes: superoxide dismutase
(SOD), glutathione peroxidase (GPx) and catalase
(CAT). Also more important are the non-enzymatic
antioxidants such as glutathione (GSH). Cellular levels
of antioxidants respond to levels of oxygen and
oxyradicals; which enables cells to defend against
increased oxyradical production [3]. If produced in
excess, or not removed effectively, oxyradicals result in
cellular damage. SOD dismutates superoxide (O2
·-)t o
yield hydrogen peroxide (H2O2)a n do x y g e n( O 2). H2O2
is not an oxyradical because it does not have an
impaired electron, but it must be promptly removed by
CAT [3]. Thus, high SOD activity, which results in
increased H2O2 production, must be accompanied by
increased GPx and/or CAT activity to limit injury [4].
GPx provides an effective mechanism against cytosolic
injury because it eliminates H2O2 and lipid peroxides
(products of
·OH mediated peroxidation products) by
reduction utilizing GSH [5]. GPx converts peroxides and
hydroxyl radicals into nontoxic forms, often with the
concomitant oxidation of reduced glutathione (GSHr)
into the oxidized form glutathione disulfide (GSSG) and
glutathione reductase recycles GSSG to GSH [4]. GSH
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any medium, provided the original work is properly cited.and other thiol-containing groups also play critical roles
as antioxidants. GSH participates in the reduction of
oxyradicals and its levels in the brain are high especially
during early development [5].
Since oxidative stress is systematic and some of the
oxidative products of the brain tissue do end up in the
blood, peripheral indices have been accepted to reflect
the brain oxidative injury [6]. However, there are con-
flicting data in the literature on the activities or levels of
antioxidant enzymes in patients with schizophrenia.
SOD activity in erythrocytes of schizophrenic patients
has been reported to be increased [7,8] decreased [9-11]
or unchanged [12,13]. GPx activities have been reported
to be unchanged [3,9,14-16] but also increased [7,17] or
decreased [11,18,19] and CAT activity has been found
unchanged [3,13,16] increased [20,21] and decreased
[11,15,22]. GSH is the brain’s dominant antioxidant
implicated in the pathophysiology of schizophrenia [23].
There is a 27% reduction in the cerebrospinal fluid
levels of GSH in untreated patients [24] and a similar
reduction (41%) in the caudate postmortem of schizo-
phrenic patients [25]. Previous studies recorded a signif-
icant decrease in the blood levels of total glutathione
(GSHt) [26], of GSHr [27] or of GSHt and GSHr [28] in
schizophrenic patients in comparison with controls.
Furthermore, increased risk of schizophrenia is asso-
ciated with polymorphisms of genes associated with
GSH synthesis [29,30]. To our knowledge, there are few
published studies that have evaluated the antioxidant
defense system (AODS) in the blood of first-episode
schizophrenic patients (FESP) and most of the studies
were conducted on populations of the patients with
chronic schizophrenia. Thus, it seemed interesting to
consider the medication status and the stage of schizo-
phrenia in the evaluation of the AODS changes that
manifest in patients.
The purposes of the present study were (1) to assess
whether red blood cell (RBC) SOD, GPx, and CAT
activities, plasmatic GSHt, GSHr and GSSG levels were
altered in the drug-naive FESP as compared to control
subjects, (2) if so, to further test whether altered antioxi-
dant defenses were associated with clinical characteris-
tics of patients.
Methods
1. Subject selection and diagnosis
Twenty-three patients (20 men and 3 women) with a
mean age of 29.3 ± 7.4 years (range, 19-45) were
recruited in their first-episode of schizophrenia from
consecutive admissions at the psychiatric department of
the University Hospital of Monastir. They provisionally
had DSM-IV-TR criteria for schizophrenia (n = 9) and
schizophreniform disorder (n = 14) based on the Struc-
tured Clinical Interview for DSM-IV-TR [31]. Diagnosis
was reconfirmed at 6 months by consensus. Healthy
control subjects (n = 45, 36 men and 9 women with a
mean age of 29.6 ± 6.2 years, range, 22-47) were
recruited from blood donors in the blood center of the
University Hospital of Monastir. Their current mental
status and personal or family history of any mental dis-
order was assessed by unstructured interviews.
The exclusion criteria considered for the two groups
were the same and included the following parameters:
seizure disorders, head injury with loss of consciousness,
dependence on alcohol and other substances (except
dependence on tobacco), vitamin supplementation fol-
lowed for 6 months prior to inclusion in the study, and
denial to take part in the present study. Additional
exclusion criteria for the control subjects included per-
sonal or family history of psychosis. All subjects signed
informed consent after a full explanation of the study.
The study was approved by the Local Ethic Committee
of the University Hospital of Monastir. The demo-
graphic and clinical characteristics of the FESP and the
control subjects were summarized in Table 1. Age and
gender distribution of the subjects and smoking habit
did not differ between patients and controls (Table 1).
2. Biochemical procedures
Five milliliters of blood was drawn from control subjects
and FESP by simple venipuncture between 7.00 and 9.00
a.m. after overnight fasting and tobacco abstinence for >
12 h. For the patients the blood samples were obtained
prior to the initiation of neuroleptic treatments. The
samples were centrifuged for 10 min at 3500 rpm.
Plasma RBCs were then separated, aliquoted and stored
at -80°C until analysis. For all samples, each evaluated
parameter was assayed in duplicate. Throughout the
investigations the biochemical assays were conducted
blind of the available clinical information. The total
SOD activities were determined using pyrogallol as sub-
strate by the method of Marklund and Marklund [32].
This method is based on pyrogallol oxidation by the
Table 1 Demographic and clinical features of the patients
and the controls
Demographic and clinical
features
Patients
(N = 23)
Controls
(N = 45)
p-
values
Age (mean ± SD) (years)
Min-Max
29.3 ± 7.5
19-45
29.6 ±
6.2
22-47
0.995
Gender (male/female) 20/3 36/9 0.477
Smokers (%) 56.5 46.7 0.44
SAPS score (mean ± SD) 25.4 ± 12.2 -
SANS score (mean ± SD) 29.5 ±
16.5
-
Max: maximum, Min: minimum, SAPS: Scale for assessment of positive
symptoms, SANS: Scale for assessment of negative symptoms, SD: Standard
deviation.
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-) and its dismutation by SOD.
One unit (U) of total SOD is defined as the amount of
enzyme required to inhibit the rate of pyrogallol autoxi-
dation by 50%. GPx activity was assayed by the subse-
quent oxidation of NADPH at 240 nm with t-buthyl-
hydroperoxide as substrate [ 3 3 ] .W h i l e ,C A Ta c t i v i t y
was determined using the method described by Beers
and Sizer [34] by measuring hydrogen peroxide decom-
position at 240 nm. CAT units (U/mg hemoglobin)
were determined as mmol of H2O2 consumed/s/mg
hemoglobin. The total hemoglobin content was mea-
sured as cyanmethaemogobine using the drabkin
method. The glutathione levels were measured spectro-
photometrically in deproteinized blood samples, by the
method of Akerboom and Sies [35], using 5,5 dithiobis
(2-nitrobenzoic acid). Absorbance values were compared
with standard curves generated from known amounts of
GSH standards.
3. Psychopathological assessment
Patients were rated for psychopathology using the Scale
for the Assessment of Positive Symptoms (SAPS) and
the Scale for the Assessment of Negative Symptoms
(SANS) [36]. The assessments were carried out by
trained psychologists.
4. Statistical analysis
The Windows computing program Statistical Package
for the Social Sciences SPSS 10.0 [37] was used for ana-
lyzing the data. The obtained data was presented as
mean values ± standard deviation (SD) and were ana-
lyzed using nonparametric statistics. Specifically,
between groups, comparisons were examined using
Mann-Whitney tests. The adjusted analysis of variance
(ANOVA) was used in case the parameters of age, gen-
der, and the smoking habit of the subject were found to
have some effects on the levels of glutathione and the
activities of the antioxidant enzymes. Finally, the corre-
lations existing between the antioxidant systems and the
SAPS and SANS scores in our patients were calculated
by using Spearman correlation coefficients. The differ-
ences were considered significant at values of p ≤ 0.05.
Results
1. Antioxidant enzyme activities and glutathione levels
There was no significant correlation between age and
AODS included enzyme activities and glutathione levels,
in patients or healthy controls. Similarly, there was no
effect of gender on AODS, even though the activities of
CAT and GPx were found to be affected by the smoking
habit of patients (U de Mann-Whitney = 24, p = 0.02
and U de Mann-Whitney = 25, p = 0.04 respectively).
Thus, the differences that appeared in the activities of
RBC antioxidant CAT and GPx activities were tested by
executing an ANOVA adjusted by the smoking habit of
the subjects.
In this study, no significant difference was observed in
the RBC SOD activity between FESP and control sub-
jects. RBC GPx activity was significantly higher in
patients than in healthy controls with 68.6 ± 13.5 vs.
41.1 ± 26.3 U/g Hb (F1-64 = 31.8, p < 0.001), but RBC
CAT activity was significantly lower in patients than in
controls with 212.2 ± 36.9 vs. 284.6 ± 88.2 U/g Hb (F1-
64 = 14.8, p < 0.001) (Table 2). As shown in Table 3,
GSHt and GSHr levels were significantly lower in FESP
than in control group with values: 560.4 ± 123.6 μmol/l
vs. 759.5 ± 260.9 μmol/l (U de Mann-Whitney = 214, p
= 0.001) for GSHt and 512.1 ± 117.7 μmol/l vs.732.2 ±
274.6 μmol/l (U de Mann-Whitney = 185, p < 0.001) for
GSHr, respectively. Whereas, GSSG was significantly
higher in patients than in controls (U de Mann-Whitney
= 270, p = 0.013) (Table 3). Additionally, we have not
found any significant differences between schizophreni-
form (n = 14) and schizophrenic patients (n = 9) in
terms of antioxidant enzyme activities and glutathione
levels.
2. Correlations between the antioxidant system and the
SAPS and SANS scores
T h e r ew a sap o s i t i v ec o r r e l a t i o nb e t w e e nt h es c o r eo f
SAPS and the levels of tGSH and rGSH (r = 0.50, p =
0.04; r = 0.51, p = 0.03, respectively). However, antioxi-
dant enzyme activities were not significantly correlated
to SAPS and SANS scores. Correlation coefficients
between SAPS, SOD, GPx and CAT were as follows (r =
-0.34; r = -0.11 and r = -0.11; respectively). Correlation
coefficients between SANS and SOD, GPx and CAT
w e r ea sf o l l o w s( r=- 0 . 1 2 ;r=- 0 . 1 5a n dr=- 0 . 1 2 ;
respectively) (Table 4).
Table 2 The activities of the RBC antioxidant enzymes in
the study groups
Antioxidant enzymes Patients
(N = 23)
Controls
(N = 45)
p-values
SOD (U/mg Hb)
Mean ± SD 2.2 ± 0.6 2.4 ± 0.6 0.2
Min-Max 1.5-3.8 1.7-4.6
GPx (U/gHb)
Mean ± SD 68.6 ± 13.5 41.1 ± 26.3 < 0.001*
Min-Max 28.2-122.6 22.9-70.7
CAT (U/gHb)
Mean ± SD 212.2 ± 36.9 284.6 ± 88.2 < 0.001*
Min-Max 157.3-282.5 100.3-499.3
CAT: catalase, GPx: glutathione peroxidase, Max: maximum, Min: minimum,
RBC: red blood cell, SD: standard deviation, SOD: superoxide dismutase.
*Adjusted by smoking habit
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The key results of the present study were: (1) the levels
of GSHt and GSHr significantly decreased in the drug-
naïve FESP in comparison with the control subjects. (2)
the group of FESP revealed an increased activity of GPx
and a decreased activity of CAT in RBCs. (3) a positive
correlation exists between the score of SAPS and the
levels of GSHt and GSHr. The findings of this study
indicate that some FESP may be poorly equipped to
deal with oxidative stress due to impaired antioxidant
defenses. Moreover, oxidative stress might play a role in
the brain’s developmental and maturational processes in
the pathogenic cascade of schizophrenia. The findings
reported above suggest such a possibility and call for
more systematic research on the role of oxidative stress
in schizophrenia.
The detailed neurochemical mechanisms underlying
the pathophysiology of schizophrenia are not clearly
understood. There has been accumulating evidence sup-
porting the involvement of oxidative stress in the patho-
physiology of this disease [2]. Prabakaran et al. [38]
reported that transcript, protein and metabolite altera-
tions are associated with the mitochondrial function and
oxidative stress in the cortex, the liver and the RBCs
of schizophrenic patients. The antioxidant system
eliminates reactive oxygen species to maintain a reduced
environment in cells through enzymatic or non-enzy-
matic approaches. The most studied antioxidants are
the SOD, GPx and CAT enzymes. Notably, CAT and
SOD, acting in concert with GPx, constitute the major
defense or primary antioxidant enzymes against super-
oxide radicals [39]. However, it is important to under-
line the contradictions and the controversial outcomes
found in the literature. In fact, these differences can be
due to several variables among which are inclusion and
exclusion criteria for patient selection, analytical meth-
odologies, testing materials (blood cells vs. plasma or
serum), exposure to medication (naïve vs. drug withdra-
wal vs. medicated), stages of the disease (acute vs.
chronic or active vs. remission phase), lifestyle or dietary
pattern, and the patient’so r i g i n .T h em a i nr e a s o nf o r
the difference between the current study and those pre-
viously reported [3,24,40], is likely to be the early stage
of illness of our patient sample. Also, our study focused
on drug-naïve FESP to show whether the oxidative dis-
turbances which occur during the course of the disease
can be related to the degenerative process linked to the
symptoms and/or treatment, or rather related to schizo-
phrenia and appear at an early stage of the disease. Stu-
dies comparing first-episode and chronic schizophrenic
patients would be necessary to further investigate a
stage-specific change in AODS in schizophrenia.
In our research, we tried to explore the activities of
SOD, GPx and CAT in the RBCs of our collected sam-
ples of patients and controls. In the present study, we
found that the activity of SOD, a key enzyme in the
endogenous antioxidant defense pathways, did not differ
between the FESP and controls. Similarly, Mico et al.
[41] found no significant difference in SOD activity
between early-onset first-psychosis group and the con-
trol group. Other studies have reported lower SOD
activity in neuroleptic-naïve FESP [3]. High levels of
blood SOD were reported in neuroleptic-naive schizo-
phrenic patients [8] and higher activities of SOD in neu-
roleptic-free schizophrenic patients in comparison with
the schizophrenic patients treated with haloperidol [13].
However, in our study, the levels of GPx were signifi-
cantly higher in the FESP than those in control subjects.
The same result observed in the early-onset first-episode
psychosis by Mico et al [41]. Yao et al. [13] showed also
a significant increase in GPx activity in drug-free schizo-
phrenic patients compared to treated ones. In this case,
increased GPx antioxidant activity may reflect a preced-
ing cellular oxidative stress or serve as a compensatory
mechanism. Interestingly, the CAT activity was signifi-
cantly lower in the RBCs of drug-naïve FESP than that
in control group. Other studies [3,41] showed no signifi-
cant difference in CAT activity between early-onset
first-psychosis patients and the control subjects. Raffa et
Table 3 Glutathione levels in the study group
Glutathione levels Patients
(N = 23)
Controls
(N = 45)
p-values
GSHt (μmol/l)
Mean ± SD 560.4 ± 123.6 759.5 ± 260.9 0.001
Min-max 402.9-821.2 430.6-1537
GSHr (μmol/l)
Mean ± SD 512.1 ± 117.7 732.2 ± 274.6 < 0.001
Min-max 402.9-821.2 374.8-1514.8
GSSG (μmol/l)
Mean ± SD 47.8 ± 18.1 35.4 ± 20.3 0.013
Min-max 10.6-76.6 6.5-73.2
GSHr: reduced glutathione, GSHt: total glutathione, GSSG: oxidized
glutathione, Max: maximum, Min: minimum, SD: standard deviation.
Table 4 The value of Spearman correlation coefficients
calculated between the antioxidant system and the SAPS
and SANS scores in drug free FESP
Antioxidant system SAPS scores SANS scores
Total glutathione 0.50* -0.02
Reduced glutathione 0.51* -0.05
Oxidized glutathione 0.16 0.17
Glutathione peroxidase -0.34 -0.12
Superoxide dismutase -0.11 -0.15
Catalase -0.13 -0.22
FESP: first-episode schizophrenic patients, SAPS: Scale for assessment of
positive symptoms, SANS: Scale for assessment of negative symptoms.
*p < 0.05
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neuroleptic-free schizophrenic patients.
On the other hand, it is likely that oxidative stress
injury was due to an impaired antioxidant defense in
early stage of schizophrenia. Furthermore, because of
their impaired antioxidant defense, some patients might
be vulnerable to oxidative injury in spite of their normal
oxyradical production [42]. In recent decades, biochem-
ical studies have increasingly more often focused on the
role of free radicals in the pathogenic of neuropsychia-
tric diseases such as schizophrenia [43,44]. In addition
to the impaired antioxidant enzyme activities, we also
found a decreased plasma GSHt and GSHr levels in the
drug-naïve FESP. Previous studies recorded a significant
decrease in the RBC levels of GSHt [26] or of GSHr
[27] in schizophrenic patients in comparison with the
controls. Plasmatic GSH level was significantly lower in
the FESP [41], magnetic resonance spectroscopy studies
have shown that levels of GSH were reduced by 52% in
the prefrontal cortex and by 27% in the cerebrospinal
fluid of drug-naïve schizophrenic patients [24]. However,
a spectroscopy study showed that patients with first-epi-
sode psychosis had a higher concentration of GSH in
the medial temporal lobe than control group [23].
Anomalies in GSH metabolism were also supported by
the low expression of the gene of the key GSH-synthe-
sizing enzyme, glutamate cysteine ligase modifier subu-
nit, in patient fibroblasts [30]. The GSH deficit found in
this study and in previous reports [18,25,45,46] may be
involved in membrane peroxidation and microlesions
related to dopamine, which seem to be increased in psy-
chosis, and suggest that GSH may be a possible indirect
indicator of damage in neuronal membranes [47,48].
This study of the drug-naïve FESP also suggests that the
deficit in GSH may underlie the pathophysiology of the
disease and is not a consequence of treatment. The con-
verging data in literature, in agreement with our results
in FESP, indicate that psychosis is associated with an
important brain glutathione deficit. In fact, it could be
hypothesized that different etiological mechanisms con-
verge into precipitating a first psychotic episode in indi-
viduals with a limited GSH synthesis capacity, after
which the psychotic episode develops into a degenerat-
ing condition that we call schizophrenia. This could be
tested by analyzing glutathione in high-risk populations
that are subsequently followed up.
In our patient group, using the SAPS, the presence of
positive symptoms was associated with higher levels of
GSHt and GSHr. Positive symptoms are associated
with subcortical dopamine hyperactivity in schizophre-
nia [49]. Several studies have revealed that catechola-
mines, especially dopamine, are associated with free
radical generation [47-49]. As suggested in the present
study, this may serve as a compensatory or protective
mechanism employed to neutralize oxidative stress
produced from presumably supra-physiological pre-
frontal dopamine. Therefore, the hyperdopaminergic
state in schizophrenia, induced by still unknown
mechanisms, may explain the positive association
between positive symptoms and GSH levels in the pre-
sent study. Although, we should be cautious, our find-
ings support the possibility of using peripheral markers
of oxidative and antioxidative system in FESP, taking
into account the special sensitivity of the brain to oxi-
dative damage [50].
This study has some limitations. Diagnostic groups
were relatively small, and it was difficult to establish in
a d v a n c eas a m p l es i z et op e r f o r mt h ed a t aa n a l y s e s
because of the paucity of studies with similar design
characteristics. A second limitation was the used sam-
ples were limited to blood ones. Because the data pre-
sents changes in peripheral blood, further work is
needed to determine if such changes adequately reflect
changes in the brain. Although, recent findings have
identified a genetic origin of GSH deficit, which results
in the impairment of the GSH synthesis in patients diag-
nosed with schizophrenia [51]. The decreased levels of
GSH and/or the activities of antioxidant enzymes in the
peripheral blood of the patients may indicate the occur-
rence of a systematic reaction that may cause oxidative
stress in the brain of schizop h r e n i cp a t i e n t sa si st h e
case in other disorders of the central nervous system
[52]. The strengths of the study are the uniformity in
age with first-episode and drug-naïve of schizophrenic
patients, and the existence of a control group.
Conclusion
In summary, our study shows that there is impairment
in the AODS in drug-naive FESP. GSH deficit seems to
be implicated in psychosis, and may be an important
indirect biomarker of oxidative stress in first-episode of
schizophrenia. Our results provide support for further
studies of the possible role of antioxidants as neuropro-
tective therapeutic strategies for schizophrenia from
early stages [6]. Data from the longitudinal study will
clarify the possible utility of peripheral markers of oxi-
dative stress as prognostic factors and the effect of neu-
roleptic drugs on oxidative stress.
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